Figures computed from official regulatory filings — .
Analysttarget 10.22 USD (+600%) · consensus 4.88/5 · 8 buy · 0 hold · 0 sell
Ownershipinsiders 2.15% · institutions 101.14% · short 17.4% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for PALISADE BIO, INC. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
72 buys38 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Williams Donald Allentrack record | Buy | $14.6K | conv 48 |
| Williams Donald Allentrack record | Buy | $14.2K | conv 58Unusual size | SEC |
| Finley John Davidtrack record | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Finley John Davidtrack record | Gift | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Baltera Robert Jr.track record | Buy | $39.8K | conv 24 | SEC |
| Baltera Robert Jr.track record | Buy | $48.9K | conv 29 | SEC |
| Jones Mitchell Lawrence | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Baltera Robert Jr.track record | Buy | $41K | conv 32 | SEC |
| Jones Mitchell Lawrence | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Finley John Davidtrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Baltera Robert Jr.track record | Buy | $61K | conv 42Unusual size | SEC |
| Finley John Davidtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jones Mitchell Lawrence | Sell | $106.5K | SEC |
| Finley John Davidtrack record | Sell | $303.3K | SEC |
| Finley John Davidtrack record | Exercise | $93.1 | SEC |
| Finley John Davidtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Baltera Robert Jr.track record | Buy | $19.8K | conv 28 | SEC |
| Baltera Robert Jr.track record | Buy | $39.6K | conv 38First in 12mo | SEC |
| Baltera Robert Jr.track record | Award | n/a (No price was disclosed in the filing) | SEC |
| Wei Binxian | Award | n/a (No price was disclosed in the filing) | SEC |
| Chuang Emil | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Williams Donald Allentrack record | Award | n/a (No price was disclosed in the filing) | SEC |
| Wei Binxian | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Williams Donald Allentrack record | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Chuang Emil | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |